Drug intelligence / Profile preview

chrysanthemum granules

Development stage: Preclinical
Lead developer: First Affiliated Hospital of Hunan University of Chinese Medicine
Administration: Oral

Overview

Chrysanthemum granules is a Traditional Chinese Medicine (TCM) preparation consisting of concentrated extracts from the flowers of *Chrysanthemum morifolium*. It is currently being evaluated in clinical trials by The First Hospital of Hunan University of Chinese Medicine for the treatment of age-related dry eye disease. The drug is administered orally as an adjunct to standard sodium hyaluronate eye drops. Its therapeutic effect is attributed to its anti-inflammatory and antioxidant properties, which are hypothesized to improve the ocular surface microenvironment and modulate metabolic pathways associated with lacrimal gland dysfunction and tear film instability.

Other names: Ju Hua KeliChrysanthemum morifolium granulesChrysanthemum extract granules

Beyond the preview

Go deeper on chrysanthemum granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chrysanthemum granules.

Explore the full profile